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Abstract
Attenuation correction (AC) in PET/MRI is difficult as there is no clear relationship
between MR signal and 511 keV attenuation coefficients (µ). One strategy is to align a
pre-defined atlas of µ to the PET/MRI for AC. However, atlas design may influence
quantitative accuracy of AC. In this thesis we compare 3 atlas design strategies and
evaluate their performance in an oncology patient population. The 3 strategies were:
correction with BMI-dependent atlases; gender-dependent atlases, and a gender- and sexindependent atlas. Patients were imaged with FDG PET/CT and 3T MRI. The atlases
were created and then used for PET AC of patients not included in the atlas construction.
Resulting PET images were compared to CT-based PET reconstructions across all voxels
and tissue-specific volumes. For the purposes of AC, there is value in developing
specialized atlases. To this end, gender plays a more important role than body mass
index in atlas construction.
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Chapter 1

1

Oncology Imaging in General

Medical imaging is an integral component of comprehensive cancer care, whether
looking at biological or pathological processes. It provides us with many benefits, which
include minimal to no invasiveness, real time monitoring, and can provide us with
valuable information over wide ranges of time and size scales (1).
The importance of medical imaging is constantly growing in all aspects of cancer care
(2, 3). Some of the ways we are seeing medical imaging contribute include aiding with
prediction (4), screening patients (5), preoperative staging (6), planning therapy (7),
therapy guidance (8), and seeing how patients respond to therapy (9, 10). Some of the
modalities that have been instrumental in this progress include X-ray Computed
Tomography (CT), Magnetic Resonance Imaging (MRI), Single Photon Emission
Computed Tomography (SPECT) and Positron Emission Tomography (PET); and more
recently examples have emerged of multiple modalities being coupled together in socalled “hybrid” modalities.

1.1 X-ray Computed Tomography (CT)
X-ray CT is among the most important of imaging technologies in cancer diagnosis and
staging, and plays many roles. For example, CT can be used for virtual colonography
(11), providing information about colon tumors themselves as well as metastases in the
lymph nodes and the liver (12, 13). X-ray CT is also frequently used to guide
interventional procedures. Some of these include guided brachytherapy (14, 15),
radiofrequency ablation of hepatic metastases and hepatocellular carcinoma (16), renal
tumours (17), and of bone metastases (18), as well as transcatheter arterial
chemoembolization (19), and guided biopsies (20-22).
In recent years, there is a growing trend of using X-ray CT for whole-body screening;
however this application has received mixed opinions. For example, in a large study of
1192 patients, 14% of scans were completely negative for any findings. Of the remaining
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86%, only 4% had a previous medical history reported. The majority of findings were
benign, and 37% were recommended for additional evaluation (23). With so many of
these findings being benign or requiring additional evaluation, one might question if there
is a more efficient and lower risk modality for performing whole-body screening.
Conversely, some progress has been made to reduce dose in X-ray CT scanning.
Recently, iterative reconstruction algorithms, originally developed for high-noise nuclear
medicine tomographic applications, have been ported to CT. These methods allow
radiation dose in CT scanning to be reduced without sacrificing image quality. Various
iterative reconstruction techniques have seen dose reductions from 25-65% (24-26).
X-ray CT has also seen a growing convergence with radiotherapy treatment
planning (27-29), which has promoted the use of larger x-ray detectors and higher power
x-ray tubes. These developments, along with temporal gating of scanning (“4D”
scanning) has improved the usefulness of CT for tumour tracking at every point
throughout the breathing cycle. Combining this with Intensity Modulated Radiotherapy,
an advanced type of high-precision radiation therapy that also relies upon temporal
gating, improves the ability to deliver efficacious therapeutic radiation doses to the tumor
site while sparing surrounding tissue (30).

1.2 Magnetic Resonance Imaging (MRI)
MRI is among the most flexible of imaging modalities in terms of its ability to derive a
multitude of contrasts from both endogenous tissue properties, as well as detect the
presence of exogenous contrast agents introduced into the body.
The majority of clinical MRI relies on signal derived from the hydrogen nuclei. The
hydrogen nuclei consist of a single proton and, therefore, have a net magnetic moment
and spin of 1/2. Hydrogen nuclei are most abundant in tissue, water and lipids and act
like microscopic bar magnets rotating along their longitudinal axis.

Typically, the

magnetic moments of hydrogen protons within a sample are oriented in random
directions, resulting in no net magnetization of the sample at the macroscopic level.
However, when the sample is placed within a strong static magnetic field, the protons
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will start to precess about the orientation of the static field. The proton will then be in a
mixed energy state composed of two eigenstates referring to the direction of the
longitudinal component of the proton’s magnetic moment: the parallel state and the
antiparallel state. Over a brief period of time, energy exchange with the surrounding
lattice through thermodynamic processes (rotations and vibrations) will result in a slight
excess of protons in the parallel state (i.e. lower energy state). This will result in the
acquisition of a net macroscopic magnetization by the sample in the direction of the
MR’s static field. This net magnetization is where we derive our signal to produce our
image.

The frequency of the proton’s precession is determined from the Larmor

equation:

ω = γ B0
where γ is the gyromagnetic ratio, which is equal to 42.6 MHz/T and B0 is the main
magnetic field strength of the MR scanner. In order to exploit resonant absorption of the
MR transmitted RF electromagnetic field, the frequency must be selected to match at the
precessional frequency of the protons, which is calculated via the Larmor equation. The
RF field produces a new effective direction of the magnetic field experienced by the
protons and they will start to precess around this direction, resulting in the net
magnetization rotating away from the longitudinal direction of the main field. The
amount of rotation, or the flip angle, depends on the strength and duration of the RF
pulse.

A flip angle of 90o will maximize the amount of transverse magnetization

produced. This is important as only the transverse component of the magnetization will
induce a detectable signal in the MRI receiver coil.

The same inter-molecular

interactions that allowed the formation of the macroscopic magnetization, T1 processes,
will force the return of the magnetization to its equilibrium state along the direction of the
main field. The rate at which the magnetization returns to the longitudinal axis is
different for protons in different tissues. It is this tissue-specific variation in the rate of
its magnetization’s return to equilibrium which provides the fundamental source of
contrast in T1-weighted images.
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T2 is a parameter that characterizes the rate of dephasing, or loss of coherence, of the
protons associated with a given tissue.

Transverse relaxation begins with the net

magnetization aligned perpendicular to the direction of the main field.

As spins

experience random field fluctuations due to the field produced by the movement of
neighboring spins, the phase of the individual spins forming the macroscopic
magnetization progressively loses coherence and the resulting magnitude of the vector
sum diminishes exponentially with time. Different tissues have different T2 values due
to their different molecular composition and therefore, T2 decay is another source of
contrast in MRI.
Echo Time (TE) is the time between the peak of the excitation RF pulse and the peak
of the echo that is formed from rephasing of the spins. Repetition Time (TR) is the time
that it takes to run through the pulse sequence once. The pulse sequence typically needs
to be repeated 256 times to construct an image with 256 lines. TE and TR can be used to
control the amount of “weighting” of these T1 and T2 effects in our image. A change in
TR will control the amount of T1-weighting and a change in TE will control the amount
of T2-weighting.
Many MRI-based methods can be applied to cancer detection and staging, evaluation
of therapeutic response and even biopsy guidance. Herein, our literature survey will list
only a few examples meant to illustrate the flexibility of MRI.
An application of MRI that is growing rapidly in profile is breast imaging. Breast MR
imaging is very important for staging because of its ability to show multi-focal tumours,
involvement of other anatomy, and presence of metastases. MRI has been shown to be
superior to ultrasound and mammography for assessing pathological response to
treatment and a low rate of re-operation (9.5%) for positive margins after breast
conserving surgery (31). This makes MRI an important tool in aiding clinical decisionmaking between breast-conserving surgery versus mastectomy.
Another area receiving increased attention for oncological applications is MRI
Diffusion Weighted Imaging (DWI), a method in which the MRI contrast is dependent on
the ability of water molecules to diffuse freely within the tissue. This has utility in cancer
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imaging because tumour tissue tends to feature microstructural abnormalities that affect
the diffusion of water molecules and lower the apparent diffusion coefficient (ADC).
This allows the tumors to be detected as bright signals on diffusion-weighted images and
signal voids on ADC maps. DWI is also useful in monitoring therapeutic response since
observed increases in ADC following therapy are thought to result from cellular water
being freed into the extracellular space following cancer cell death (32). Therefore, a
positive response to therapy is indicated by a rise in ADC. An example of this can be
seen with changes in hepatic metastases from neuroendocrine tumours following
transarterial chemoembolization imaged with DWI MRI of the liver (33).
As with many medical imaging modalities, MRI images can rely upon either
endogenous contrast or exogenous contrast agents introduced into the body. There are
many examples of the latter; however, one exogenous contrast agent that has been
attracting considerable attention recently is Ultra Small Particle Iron Oxide (USPIO).
Accumulation of this contrast agent causes a sharp reduction (loss) in an MR imaging
parameter known as T2*. An example of USPIO application is in the detection of lymph
node involvement in the spread of cancer from a primary tumor site. In many cases,
diseased lymph nodes become enlarged, relative to their healthy counterparts – making
the diseased nodes easy to detect. However, diseased nodes, which are not enlarged
become difficult to detect. In a recent study, combining USPIO MRI and a different
imaging modality - Positron Emission Tomography using the 18F-based radiotracer
fluorodeoxyglucose - achieved 100% sensitivity, specificity, positive predictive value,
and negative predictive value in diseased lymph node detection in breast imaging, as
confirmed by histopathology (34). Further to this success, USPIO MRI is also receiving
attention in evaluating lymph node involvement with prostate, colorectal cancer and lung
cancer.

1.3 Nuclear Medicine Imaging
Nuclear medicine modalities consist of Single Photon Emission Computed Tomography
(SPECT) and Positron Emission Tomography (PET). Unlike X-ray Computed
Tomography and Magnetic Resonance Imaging, the nuclear medicine modalities do not
image endogenous contrast. However, their ability to detect their associated gamma-ray
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emitting exogenous contrast agents remains far unchallenged. SPECT, and moreso PET,
are capable of detecting contrast agents in the nanomole/kg and picomole/kg
concentrations. In comparison, X-ray CT has sensitivities of a few millimole/kg, while
MRI sensitivity has been reported to be approximately 10 millimole/kg (1). The high
sensitivity of nuclear medicine modalities allows the use of relatively little exogenous
contrast and the benefit of having an exceedingly low rate of pharmacological reaction
(1).
In both SPECT and PET, the exogenous contrast agent is referred to as a radiotracer.
It is comprised of a radioactive atom that emits gamma-rays upon its radioactive decay;
and a molecule that has biological relevance. The biological relevance can include
affinity to certain types of cells, or properties that facilitate or prevent diffusion across a
membrane. In general, these radiotracer properties allow detection of cell populations,
measurement of filtration or blood flow, and, by extension, the differentiation of diseased
tissues from healthy tissues. In many cases, abnormal tracer uptake can be indicative of
disease processes such as cancer (35) or tissue damage, as would be the case following a
heart attack (36). SPECT and PET are often referred to as functional imaging modalities,
since they show tissue health, rather than anatomical structure. SPECT and PET differ in
that the latter relies upon the detection of pairs of gamma-rays, in contrast to Single
Photon Emission Computed Tomography.
Both SPECT and PET have a multitude of uses in oncology. For SPECT, we will
survey two examples that have received increased attention in recent reports. We will
then turn our attention to PET, where exciting applications are growing at an exponential
rate.

1.3.1

SPECT

A long-standing, but growing, application of oncologic SPECT is in the identification of
the Sentinel Lymph Node (SLN), which is the first lymph node met by lymphatic vessels
draining a tumour (37). The absence of tumour cells in the SLN could indicate the
absence of metastatic disease in other surrounding nodes. If the SLN is identified and
found to contain no tumour cells, extensive node dissection surgery can be avoided.
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Lymph node drainage patterns can be seen by SPECT using 99mTc-labelled human serum
albumin (38, 39). In a review of 14 articles on the role of SPECT/CT – a form of SPECT
that is combined with X-ray CT – in the preoperative detection of sentinel lymph nodes
in breast cancer (40), the authors found that SPECT/CT improved both identification and
staging of breast cancer when compared with planar lymphoscintigrams.
SPECT has, and continues to, see roles in pharmaceutical development, where
radiotracer versions of therapeutic drugs are used to measure pharmacokinetics and
identify the ultimate fate of the drug. Here, SPECT has accelerated drug development and
minimized the effort spent on ineffective treatments for cancer patients (41). An example
of this can be seen with the use of folate-targeted imaging agents to predict response to
therapy with folate-targeted therapy in advanced ovarian cancer (42). In this study it was
suggested that use of folate receptor targeted EC20 (a

99m

Tc-labeled imaging agent)

imaging can identify patients with advanced ovarian cancer who are most likely to
benefit from therapy with folate receptor targeted EC145.

1.3.2

PET in Oncology

PET, like SPECT, seeks to measure the distribution of an administered radiotracer. In the
case of radiotracers designed for PET, however, the radioactive atoms on the tracers do
not themselves emit gamma-rays. Instead, they decay (often but not always) by emitting a
positron – the anti-matter counterpart to the electron. This positron travels a certain
distance, determined by its kinetic energy, and then interacts with an electron in mutual
annihilation, leading to the emission of two 511 keV gamma-rays in nearly opposite
directions. The PET scanner detects these two gamma-rays in near time-coincidence. By
repeatedly detecting these events, the PET scanner is able to measure projections of the
distribution of the administered radiotracer. Then, using the principles of computed
tomography, similar to those found in SPECT and X-ray CT, these projections are
combined to create a three-dimensional representation of the radiotracer distribution in
the body.
PET has seen broad applications in oncology, cardiology and neurology. It features a
number of advantages over its single photon counterpart: more flexible radiochemistry
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which allows a greater selection of radiotracers to be developed, shorter half-lives of
radionuclides simplifying repeat studies in individuals, and increased sensitivity to low
concentrations of radiotracers. However, PET has always been more expensive than
SPECT, which contributed to its smaller deployment historically.
However, in the 1990s, an important invention was made that would change PET –
and many imaging modalities – forever: the hybridization of imaging modalities. A PET
scanner was combined with an X-ray CT scanner, leading to PET/CT (Patent No: US
6,490,476 B1; Townsend, D.W et al, Nuclear Science Symposium, 1998. Conference
Record. 1998 IEEE). Now, for the first time, the exquisite biological information made
available via visualizing radiotracer distribution was combined with the anatomical
referencing made possible with X-ray CT. This is in part why PET/CT has become such a
powerful tool for the detection of cancer. For example, in conjunction with the
radiotracer

18

F-FDG, the sensitivity of PET/CT aids in the early detection of tumours,

allowing for early treatment (43) and its high specificity aids in the identification of nonspecific benign lesions (44, 45). In tumor staging: FDG-PET has been found to be more
accurate than CT in staging disease in the mediastinum in patients with lung cancer (46).
Further still, integrated FDG-PET/CT has been found to be even better at predicting stage
I and II disease as well as size of the tumor and whether it has invaded nearby tissue (T)
and regional lymph nodes that are involved (N), of patients with non-small cell lung
cancer (NSCLC) when compared with dedicated PET alone. There were similar findings
in a study of 27 patients with lymphoma, which concluded that FDG-PET/CT imaging
was accurate in re-staging lymphoma and offered advantages over separate FDG-PET
and CT imaging (47). In the same way that SPECT can be used to assess cancer response
to a therapeutic prescription to determine efficacy early on during treatment, PET can be
used for follow-up scans to detect progressive disease or recurrence. Van Loon et al
(2009) found that PET-scanning after curative treatment for NSCLC led to the detection
of progression, and that selectively offering a PET/CT scan to the patients without
symptoms could possibly lead to an effective follow-up method (48).
Also, like SPECT radiotracers, drugs can be labelled with a radionuclide without
changing the drug’s biochemical properties. This makes it possible to use trace quantities
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of a drug to predict its pharmacokinetics and distribution at therapeutic quantities with
less probability for unintended reactions. Various radiolabeled chemotherapy agents have
been studied, such as [18F]tamoxifen (49), [18F]fluorouracil (50), and [18F]paclitaxel (51).

1.3.3

18

F-fluorodeoxyglucose (FDG)

Of the many potential radioisotope tracers that could be used in PET imaging, FDG is
one that has proven most useful particularly in oncology imaging. FDG is a molecule that
is very similar to glucose, and shares many – but not all – of its biochemical traits.
FDG is labeled with the radionuclide 18F. A popular method for producing 18F is in a
medical cyclotron. A cyclotron is a particle accelerator used to accelerate charged
particles outwards from the center along a spiral path (Figure 1-1).

Electromagnet (North Pole)
Particle’s Spiral
Charged Particle

Path

Target

Acceleration

Hollow Electrode
Chambers (Dees)

Electromagnet (South Pole)
Alternating Current
Source

Figure 1-1: Cyclotron - Positive ions created inside are accelerated between the hollow
electrode chambers (Dees) by a square wave electric field, which reverses just as the ions
approach the gap. The ion path spirals away from the center, perpendicular to the field
direction until they collide with the target.

A static magnetic field holds the particles to the spiral path and they are accelerated by a
rapidly varying electric field. In the case of
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F, the cyclotron is used to bombard

18

O
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atoms (chemically present as

18

O enriched water) with high energy protons, resulting in

the reaction:

The FDG molecule itself differs from glucose in that the 18F substitutes for a hydroxyl
group in the 2’ position, as shown in Figure 1-2.

Figure 1-2: 2-Deoxy-2-(18F) Fluoro-D-Glucose
In the body, glucose is central to the production of metabolic energy. Typically,
after glucose is consumed by an individual, it becomes distributed in the blood, and is
taken up by cells via membrane-bound glucose transport proteins (See Figure 1-3). Inside
the body’s cells, glucose interacts with an enzyme known as hexokinase, and becomes
phosphorylated, forming glucose-6-phosphate. This new molecule then reacts with
glucose-6-isomerase to form fructose-6-phosphate, and finally enters the Krebs cycle.
FDG, like glucose, enters the cell via membrane transport proteins; and then
undergoes phosphorylation by hexokinase. However, the resulting FDG-6-phosphate
cannot interact with glucose-6-isomerase, and hence does not proceed to the Krebs cycle.
Instead, FDG-6-phosphate merely accumulates in the cell – where it ultimately serves as
an indicator of glycolytic activity. This feature of FDG makes it extremely useful in
oncology since glycolysis is greater in many tumour cells than in their healthy
counterparts (52). In general, the increased FDG observed in cancerous tissue is due to
upregulated activities of glucose transporters (GLUT1 and GLUT3) and hexokinases (I
and II) (53, 54). Although glycolytic rate can be regulated at many different steps in the
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glycolytic pathway (55, 56), the majority of studies on this process in cancer suggest that
control over glycolytic flux is found at the transport and phosphorylation level (57-59).
As a result, FDG accumulates in cells with high metabolic activity.

1.3.4

Positron Emission Tomography – The Scanner

A PET scanner is physically arranged as a ring, or multiple rings stacked axially, of
detection elements surrounding the region to be imaged (See Figure 1-4). The rings are
comprised of circumferentially placed block detectors facing inwards. The block detector
itself consists of an inorganic scintillation crystal and a square array of photomultiplier
tubes (PMTs), and is in essence a miniature version of the gamma camera that is used in
SPECT imaging.
The role of the scintillation crystal is to absorb, via the photoelectric process,
incoming gamma-rays and convert them into an optical fluorescent signal that is
detectable by the PMT array. Considerable effort has been placed into the development of
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scintillation crystals. Until the late 1990’s the near-ubiquitous choice of crystal was
Bismuth Germanium Oxide (Bi4Ge3O12, or simply BGO), which provided excellent traits
for detection of 511 keV gamma-rays. More recently, however, BGO is being supplanted
by lutetium oxyorthosilicate (Lu2SiO5, or LSO), which features superior gamma-ray
count rate capability, but has the disadvantage of being slightly radioactive (featuring a
beta decay of natural 176Lu).

Photomultipliers

Scintillation
Crystal
Detector Block

Figure 1-4: A schematic diagram of rings of gamma detectors of a PET scanner. The
inset schematically shows an example of a detector block configuration.

Behind the scintillation crystal is an array of PMTs. A PMT is a type of vacuum tube
that is extremely sensitive to light detection (in the near-ultraviolet to near-infrared range
of the electromagnetic spectrum). A PMT uses a sequentially-arranged series of dynodes
to multiply the current produced by incident light many millions of times, enabling the
detection of even individual photons.
The PMTs are spatially arranged behind the scintillation crystals to detect fluorescent
light output following the absorption of a gamma-ray, where PMTs closer to the gammaray absorption will receive more light signal. Each PMT is connected to electronic
circuitry to reflect the relative amount of light sensed by the array. When a gamma-ray
impinges on the scintillation crystal, all PMTs detect simultaneously the same flash of
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light to varying degrees, depending on their spatial position from the individual event.
Thus the spatial location of each “flash” of light in the scintillation crystal is reflected as
a pattern of signals within the interconnecting array. The pattern of signals, specifically
the relative amount of light from each PMT, is then interpreted by a computer to identify
the location of the scintillation event in the crystal. The summation of all signals from the
PMT array is proportional to the total energy of the absorbed gamma-ray.
Since it is known a priori that PET radiotracers emit 511 keV gamma-rays in
opposite directions but simultaneously, the PET scanner purposefully seeks gamma-rays
being detected in near time-coincidence (with an acceptance window of typically 6 to 12
nanoseconds). If two gamma-rays are registered as coincident, it becomes possible to
identify their point of origin as being along a line joining the spatial locations of the
detection events. This line is termed a line-of-response (LoR). By measuring hundreds of
thousands of detection events along different LoRs, the resulting data can be sorted into
projections of the distribution of the radiotracer inside the body. These projections can
then be reconstructed using various algorithms into three-dimensional tomographic maps
of the radiotracer distribution.

1.4 Challenges with Quantification
PET, even more than SPECT, has focused on quantification and quantitative accuracy.
This was driven mostly by the role of PET being restricted, before PET/CT, to academic
centres. However, quantification is not straightforward, as detecting and positioning
gamma-rays is compromised by the physical processes of scatter and attenuation;
whereas, the PET scanner itself is bound by limitations in gamma-ray count rate
capabilities, and position detecting of gamma-rays. These phenomena must be accounted
for, and broadly speaking this is accomplished by way of detector normalization, and
corrections for random coincidences, and scattered and attenuated gamma-rays. We will
describe each in turn.

1.4.1

Detector Normalization

PET scanners are comprised of hundreds of individually-cut scintillation crystals. Each of
these crystals can have slight variations in dimensions, and quality of optical coupling
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between the crystal and the underlying PMT array. Hence, the efficiency of the
conversion of gamma-ray energy to an electrical signal varies between block detectors.
These differences lead to variations in sensitivity and resolution across the field of view
(FoV). Correcting for these variations to achieve uniformity is termed normalization.

One approach to normalizing detectors is to record the number of counts detected by
each coincidence pair of detectors during exposure to a uniform radionuclide source.
With the radionuclide source extended through the axial FoV and rotating it around the
periphery once, all detector pairs are exposed to the same number of gamma-ray pairs. As
some detector pairs will record more counts and some will record fewer counts, the
normalization factor for each detector pair (a,b) is calculated from ,

NormFactor(a,b) = Counts(a,b) / AvgCt ,
where Counts(a,b) is the number of counts for detector a and b, and AvgCt is the average
counts for all detector pairs. This can then be used to correct the number of counts for
each detector pair by,

Corrected(a,b
(a,b)) = NewCounts(a,b) / NormFactor(a,b)
where NewCounts(a,b) is the uncorrected count number for a patient scan. This is applied
to the projection data before proceeding to tomographic reconstruction.

1.4.2

Random Coincidence Correction

A random coincidence occurs when two unrelated positron annihilation events occur
simultaneously, and a single gamma-ray from each of those events is detected in time
coincidence and then erroneously paired along a LoR (Figure 1-5). The net effect of such
random coincidences is to add a relatively uniform background of counts across the FoV,
ultimately suppressing image contrast and distorting the relationship between the true
concentration of radiotracer in a location compared with its measured amount.
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A very popular method for correcting the effect of random coincidences is by
acquiring a delayed window. As stated previously, individual gamma-rays tagged with
their detection times and a valid event are recorded when two detection events occur
within a specified coincidence timing window. Interestingly, the rate of random
coincidences can be estimated by purposefully pairing gamma-rays that arrive at different

LoR

Figure 1-5: A schematic showing a Line of Response (LoR) from a random coincidence
event.

times, which is practically implemented by temporally shifting the coincidence
acceptance window for one of the detectors by an amount greater than the length of the
window itself. The delay prevents the detection of any true gamma-ray pairs, and instead
represents an estimate of the distribution of random coincidences that are unintentionally
detected with coincident timing windows. The estimate of random coincidences can then
be subtracted directly from the data needing to be corrected.
Since the recorded random coincidence rate is only a sample rate and not an actual
account of randoms occurring in the undelayed window, the subtraction of this value does
introduce some statistical noise. This uncertainty remaining after subtraction can be
represented with the following,
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σ(Trues + scatter) =
where Trues is the number of true coincidence events, Scatter is the number of scattered
coincidence events and the Randoms is the number of random coincidence events.

1.4.3

Scatter Correction

A scatter coincidence occurs when one or both annihilation gamma-rays are deflected,
inside the patient or inside the scintillation crystals, from their original trajectories by
Compton scattering but are nonetheless detected in time coincidence (Figure 1-6).
Similarly to the presence of random coincidences, the presence of scattered coincidences
compromises spatial resolution and quantitative accuracy, and results in reconstructed
images with a background “haze” that is more prevalent towards the center of the FoV.

Figure 1-6: A schematic showing a Line of Response (LoR) from a scatter coincidence
event.
The subject of scatter correction has received considerable attention for decades in
PET physics literature. The class of scatter correction most widely implemented today is
the iterative model-based scatter correction (60). Although specific implementations
vary, the general methodology is as follows: the correction begins with (i) a measurement
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of the projection data that includes both useful data as well as scattered data, and (ii) a
measurement of the distribution of density inside the object being measured. The first
step is to ignore the presence of scatter in the projection data, and perform a preliminary
tomographic reconstruction. Next, a computer uses the preliminary reconstruction, the
distribution of object density, and a model of photon propagation to simulate the
distribution of scatter that PET scanner would have recorded, resulting in an estimate of
the scatter distribution. This scatter estimate is then subtracted from the measured
projection data, resulting in a slight reduction in the amount of scatter in the projection
data. The process can be repeated several times, but no objective criteria for determining
the optimal number of iterations has been agreed upon broadly.

1.4.4

Attenuation Correction

Attenuation is the gradual loss of signal intensity as it passes through a medium. It is an
important source of error in both SPECT and PET imaging, and is observed often as a
broad reduction in radiotracer concentration in the central FoV of tomographic
reconstructions. Attenuation can also manifest more subtly, appearing as localized
reductions in radiotracer concentrations in cardiac and liver imaging, which can adversely
affect diagnostic accuracy.
As with scattered coincidences, the origin of the attenuation phenomenon lies with
the physical process of Compton scatter. However, in the case of attenuation, at least one
of the gamma-rays is scattered away from the PET detector rings, and is “lost”. Also, as
with scatter, modern techniques for attenuation correction rely upon an estimate of the
distribution of material that is causing the Compton scattering. With such an estimate in
hand, one can effect an attenuation correction in a manner similar to that described earlier
for scatter correction.
The accuracy of scatter and attenuation corrections is determined by both the quality
of the physical models of gamma-ray propagation, as well as the quality of the density
measurement of the object through which the gamma-rays are propagating. This density
measurement is more specifically a measurement of the spatial distribution of linear
attenuation coefficients within the FoV of the PET scanner. This is often termed a “µ-
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map”, where µ is a common symbol for linear attenuation. The estimation, or
measurement, of µ-maps has seen considerable evolution since the inception of PET,
with each generation of technique typically improving in spatial resolution and contrast,
and decreasing in noise and acquisition time. Strategies for generating µ-maps fall into
two categories: non-transmission strategies that rely solely upon the measured radiotracer
distribution, and transmission strategies that rely upon an independent measurement of
tissue attenuation coefficients.

1.5 Attenuation Correction Methods
1.5.1

Non-Transmission µ-maps

Non-transmission µ-maps are generated by analyzing properties of the radiotracer
distribution in the projection data. Generally, the assumption is made that the observed
radionuclide distribution is bounded by a single convex hull, such as an ellipse,
characterized by a single uniform attenuation coefficient within its perimeter. The
boundary of the ellipse can be estimated by a trained operator or an edge detection
algorithm applied to the emission data.
Although relatively simple to implement and easy for an operator to use, drawing
contours manually often does not result in perfect “fits” to patients, the quality of fit will
vary between operators, and a uniform distribution may not account for the true
heterogeneity of attenuation coefficients within a patient’s body (61).
One way to help improve consistency with a uniform mapping approach is to
eliminate the inter-operator variability by automating the task of contouring with edgedetection algorithms. There have been several automated approaches based on different
edge-detection algorithms. Some have made use of the Compton scattered gamma-rays
to determine the convex contour of patients (62, 63), while others have estimated the
patient outer contour directly from the unscattered projection data (64, 65), and one group
has incorporated both (66).
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1.5.2

Transmission-based µ-maps

Transmission-based µ-maps are created from direct measurements of attenuation in the
body. The principal of this measurement is very similar to x-ray CT: a known flux of
gamma-rays or x-rays passes through the body, is attenuated by it, and then detected on
the opposite side.

1.5.2.1

Radionuclide Transmission Scans

An external radionuclide source can be used to transmit gamma-rays, of one or more
discrete energy levels, through the body to map the distribution of linear attenuation
coefficients at an energy of interest. These radionuclide transmission scans can be
acquired before radiotracer injection (67, 68), after the injection but during the PET scan
(69, 70), or after PET scan (71, 72). Each option has advantages and disadvantages.
In oncologic whole-body surveys, the region to be scanned is much longer than the
axial FoV of the PET scanner. This requires the PET data to be acquired in a step-andrecord manner, where the PET scanned bed moves incrementally and longitudinally
through the PET scanner. For this scenario, a practical and simple to implement solution
is to alternate, in an interleaved manner, transmission and PET scanning for each bed
position. This however, increases patient scan time, both hindering patient throughput
and patient comfort. These interleaved scans also suffer from image registration
problems, due to patient motion or misalignment between scans.
Performing the transmission scan during the emission scan reduces scan times, but
requires the radionuclide gamma-rays to be of a different energy than the PET scan
energy (which is always 511 keV). This option results in errors in the µ-map from crosstalk between the transmission and emission scans. For example: if one chooses a
transmission radionuclide with gamma-ray energy higher than 511 keV, like 137Cs, which
emits a 662 keV gamma-ray, then some of the transmission gamma-rays will contaminate
the PET scan as they lose energy through Compton scatter. Further, if transmission
scanning is performed at a different energy than 511 keV, the attenuation coefficients,
which are energy-dependent, must be scaled to match their 511 keV counterparts.

20

1.5.2.2

X-ray CT Scans

The development of the hybrid PET/CT provided a “next generation” of attenuation
correction. Compared with radionuclide transmission imaging, CT scans could be
acquired much faster, and with higher spatial resolution and less noise. The penalties,
however, were increased financial cost (now comprised of the cost of a PET scanner plus
a CT scanner), increased ionizing radiation dose to the patient, and increased complexity
to create the final µ-map.
X-ray has one endogenous contrast mechanism with which it can provide details
about anatomy, which is electron density. This makes CT very useful for acquiring
detailed images of boney structures, but its ability to provide details about soft-tissue is
outdone by MRI.

In a prospective comparison of the accuracy of MR and CT in

determining the anatomic extent of disease in 40 patients, it was suggested that MRI
might be the modality of choice when staging soft-tissue sarcomas. In this study, 23% of
tumours observed in MR images were missed in their respective CT images (73). This
limitation of soft-tissue imaging with CT, particularly in oncology applications when
compared to MRI, has been consistent with the findings of other groups (74, 75).
Compared with radionuclide transmission scanning, X-ray CT imaging results in a
much higher flux of photons passing through the body, resulting in a higher patient
radiation dose. A typical PET scan, using 370 MBq of FDG, results in a whole body
dose of approximately 6.23-10.73 mSv (76, 77). A typical whole-body CT can impart a
dose of 7.22-25.95 mSv (76), depending on patient body size and CT protocol. This is
considerably higher than the 0.20-0.26 mSv resulting from a radionuclide transmission
scan (78). For reference, the annual background in Canada is approximately 3 mSv. For
example, assuming a detriment coefficient of 5.6×10-5 [/mSv] (20-64 yrs of age
population, References ICRP-60 and NCRP-115), the use of CT will increase the longterm risk of developing cancer by (7.22-0.20)*(5.6X10-5)*100% = 0.039. With this in
mind, many groups have begun researching dose reduction strategies for X-ray CT,
including variable current x-ray tubes, reconstruction algorithms that model the statistical
processes of x-ray measurements, and iterative reconstruction techniques.
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Both X-ray CT and some radionuclide transmission scans are acquired at different
energies than a PET scan, which is always a monoenergetic 511 keV. Thus x-ray CT µmaps, like radionuclide µ-maps, must be energy-scaled to be used for attenuation
correction. However, X-ray imaging has the added complication of using a polyenergetic
(and continuous) spectrum ranging from 40-140 kV (or about 40 kV with filtration) to the
x-ray tube kilovoltage peak, usually set near 140 kV for a tungsten anode for PET
attenuation correction. Since attenuation coefficients are energy dependent, the
coefficients measured at CT energies must be converted to their respective coefficients at
511 keV before the correction factors can be calculated. At 511 keV, the majority of
photon interactions for all biological materials are Compton scatter, whereas
photoelectric absorption is essentially negligible. However, in the CT energy range for
bones, photoelectric absorption becomes a dominate effect. To complicate this further,
the attenuation coefficients of different materials do not change in the same way when
photon energies change. However, there are translation algorithms, which use bilinear
mapping functions to perform these corrections, and they work well fundamentally
because both monoenergetic photon attenuation and polychromatic photon attenuation
are related to electron density (79, 80).

1.5.2.3

PET/MRI

PET/MRI represents the hybridization of two very flexible but very different imaging
modalities. Unlike the hybridization of PET and CT, or SPECT and CT; PET/MRI
combines modalities that exploit the properties of ionizing radiation (PET) and nonionizing radiation (MRI). To a large extent, aspects of this difference were what
complicated and delayed the development of PET/MRI.
As described earlier, conventional PET scanners use photomultiplier tubes (PMTs) to
spatially localize gamma-ray absorption in a scintillation crystal. Unfortunately, for
PET/MRI, PMTs are sensitive to magnetic fields. PMTs are often wrapped in mu-metal,
an alloy known for its high magnetic permeability and thus useful for shielding against
static or low-frequency magnetic fields. This is to partially attenuate magnetic fields, but
embedding PMTs into an MRI that generates multi-Tesla magnetic fields will still render
them useless. One approach to addressing this incompatibility was to use optical fibers to
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lead scintillation light outside the fringe of the magnetic field or at least outside the MRI
field of view (FOV) (81-88). This not only placed the PMTs outside the high magnetic
field, but also placed all metallic or magnetic PET detector parts outside the MRI FOV.
This minimizes the potential for interference with the magnetic field, gradients or
radiofrequencies. However, this approach degrades performance, and due to the physical
space occupied by the fibers, it results in PET systems with limited axial FOV (85).
Other approaches, such as in split MRI tomographs (89), or field-cycled MRI, where
the magnet is shut down during PET data acquisition (90), rely on special magnet designs
where the PET detector is built in between two magnets. These usually limit magnetic
field strength, which limits performance, because MRI signal increases with magnetic
field strength.
Alternative designs based on compact, solid-state silicon photo sensors, called
avalanche photodiodes (APDs) (91), such as the small-animal PET-MRI (85, 92, 93) and
the first clinical PET/MRI (94), are not sensitive to magnetic fields (95).
Siemen’s first clinical PET/MRI makes use of APDs, and incorporating them was no
small feat. All hardware components and assembly are optimized for both PET and MRI
detection.

Efforts have been made to minimize disturbances to detection of either

modality from the other. RF body coils are PET transparent. PET detectors are nonmagnetic and gradient transparent, so that the linearity of the gradient fields are not
distorted. The APDs need to be maintained at a stable 20ºC, which is achieved with a
water cooling system.

All PET detector electronics are completely shielded from

emitting RF signals, which may otherwise disturb the MR’s RF signals. This is done
with copper elements.
MRI RF coils have been optimized to be as PET transparent as possible, minimizing
the amount of gamma attenuation. Rigid equipment, such as the patient table, RF spine
array coil and RF head coil have been scanned in a CT to form 3-D µ-maps of each.
Similarly to how a patient µ-map is calculated for PET from a patient CT, the 511keV
attenuation values are generated for these MRI apparatuses. These µ-maps are each
registered for the PET/MRI, linked to table position, and from that point are incorporated
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into the PET reconstruction process. Other, more flexible RF coils, which do not lock
into a consistent position in relation to the patient table, cannot be corrected for
attenuation in the same manner. Instead, the goal of PET transparency is emphasized.
To achieve maximum signal-to-noise ratio (SNR) and signal for MR, without disturbing
PET image quality, specific materials, optimal geometry and assembly are used.
All of these advancements have allowed PET and MR hardware to finally be fully
integrated, but one of the outstanding challenges is how to best correct for patient
attenuation. This is a significant challenge because MRI signals are not related to the
factor that contributes to gamma-ray attenuation, which is electron density.
MRI-based attenuation correction can be divided into three categories mapping,
segmentation, and atlas-based. Mapping involves creating a mathematical function that
will convert MRI voxels to linear attenuation coeffients. Although this approach has
great potential, it is currently limited by the similar appearance of air and bone, and the
inability to map variations in lung densities. Both of these problems are due to the lack of
signal obtained from bone and lung tissues from conventional MRI pulse sequences.
In segmentation, the goal is to divide the MR images into different tissues. There
are a variety of approaches to doing this but once the tissues have been classified, they
are then assigned theoretical attenuation values. Although this approach gives us patient
specific µ-maps and can work well with tissues or mediums with consistent attenuation
coefficients, this approach does have difficulty in accounting for bone and lungs, again
due to the lack of signal. It also has difficulty accounting for image truncation, which can
occur if part of the patient is too far from the isocenter of the main field. Also, signal
noise can often cause some misclassification or incorrect segmentation.
The third approach is the atlas-based approach. This uses previously acquired
data, such as MRI and CT images, and registers them to a patient’s scan to obtain a
customized µ-map for that patient. This approach can overcome some of the problems
associated with the two previously mentioned approaches, but critically relies on an atlas
that represents the intended population.
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The current implementation of MR-based attenuation correction of PET by Siemens
uses a 2-Dixon MRI sequence to map water and fat.() This method has been shown to
provide results similar to those of conventional attenuation correction with low-dose CT()
and demonstrates the importance of accounting for these different tissues. This method
however, does not account for bone and is still vulnerable to image truncation and signal
noise. An atlas-based approach can overcome the problems of image truncation and
signal noise, as well as incorporate attenuation values for bone. However, without a
patient specific mapping what are the most important qualities to take into consideration
when constructing an atlas? The current de facto approach used with Siemens mMR
considers body fat composition to be of importance. Can body mass index be used to
improve the accuracy of an atlas? Also, with the obvious anatomical differences between
genders perhaps it is important to have gender specific atlases, and to what extent does
accounting for these attributes play a role?
The purpose of my thesis was to develop a method for MR-based attenuation
correction. Specifically, we wanted to determine the extent of which gender and body
mass index (BMI) affect quantitative accuracy of atlas-based attenuation correction in
PET/MRI.

We compared 3 approaches to atlas construction and evaluated their

performance in a general oncology population. These approaches used: Body Mass Index
(BMI)-specific atlases; gender-specific atlases; and a BMI- and gender-nonspecific atlas
(or fully amalgamated atlas).
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Chapter 2

2

A Comparison of Gender and BMI-based approaches to
Atlas Design for Attenuation Correction in PET/MRI

2.1 Introduction
Several manufacturers have recently marketed PET/MRI scanners. Many authors
speculate that this combination of powerful imaging technologies will lead to novel
methods in diagnosis and therapy management over the coming years [1-3]. Combining
PET and MRI is a complex endeavor, and many issues remain to be resolved. Among
challenges under active investigation is how to perform PET attenuation [4-7].
Attenuation in PET is caused by gamma-rays being scattered by electrons in tissue and
then failing to be detected in coincidence. Attenuation can be corrected with knowledge
of the spatial distribution of electron density, which can be measured with X-ray CT [8].
This, in part, has contributed to the success of combined PET/CT. However, MRI
measurements are more closely related to proton density and magnetic properties of
tissues rather than electron density, and therefore not easily amenable for use in
attenuation correction [7, 9, 10].
Three approaches to creating attenuation maps from MRI are: image segmentation
[2, 7, 10], mapping [5, 11], and atlas map registration [12, 13]. We and others have
published studies comparing the three PET/MRI attenuation correction methods under
various conditions [6, 12-14].

2.1.1

Image Segmentation
Image segmentation involves partitioning a 3D image volume into discrete sub-

volumes using visual quantitation, noise consideration, and a prior knowledge of
morphology [14].

These sub-volumes are assigned tissue classifications and then

attenuation coefficients are assigned using a lookup table of known values.
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Some of the challenges associated with segmentation include an absence of bone
and lung from the attenuation maps (µ-maps). This is particularly problematic in bone
lesions and areas of complex air-bone interfaces, like the paranasal sinuses [2, 7]. MRI
susceptibility artifacts and partial volume effects compromise accurate segmentation of
small features such as the vertebral column, and objects such as the tendon connecting
the lower jaw bone and the temporal muscle can often be misclassified as bone because
of reduced relaxation rates [7]. Ignoring these tissues can lead to quantitative errors in
PET reconstruction, although others have found no difference in clinical interpretations in
methods neglecting bone [2].

These quantitative errors are often shown as

underestimates of Standardized Uptake Values (SUV), which is the tissue radioactivity
concentration at a particular point in time, divided by the injected dose at the time of
injection per unit of body weight. It is calculated by,

where tissue activity concentration is in units such as MBq/kg, injected activity is in
MBq, and body weight is in kg. Despite this, some efforts have been made to obtain MR
signal from cortical bone with the addition of ultra-short echo (UTE) sequences [7].

2.1.2

Mapping
Mapping involves creating a mathematical function that will convert MRI voxels

to linear attenuation coeffients based on MRI voxel intensity. This approach has the
potential to be the most powerful and robust method of creating MRI-based µ-maps
because it can be done without making assumptions about patient anatomy or tissue
health [5, 15]. This could yield a continuous distribution of µ that spatially corresponds
to the patient’s individual anatomy. Unfortunately, difficulties with these approaches
often stem from the appearance of bone and air being too similar to resolve by a simple
histogram matching, or variations in lung densities being missed due to the lack of signal
that can be obtained from conventional MRI pulse sequences [5, 15].
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To address these problems with mapping areas of low signal, new sequences with
shorter echo times and ultra-short echo times have been used to obtain signal from lung
and bone tissue respectively. We have shown that variation in lung density between and
within patients can be mapped [5] and signal can now also be obtained from cortical bone
and mapped to corresponding linear attenuation coefficients from MRI. This can be done
within the range of clinically acceptable errors and without any assumptions being made
about patient anatomy [5, 15].

2.1.3

Atlas Map Registration
Atlas-based or registration approaches involve spatially aligning a pre-defined

spatial distribution of coefficients to a measured MRI dataset. Registering a pre-defined
atlas map critically relies on the selection of an atlas that can be adaptable to a patient
population. These approaches have the benefit of including bone in their µ-maps and
being able to easily obtain predictions outside the tomographic field of view of the MRI,
as with a larger patient’s arms when placed at their sides [2, 13]. Although these benefits
address some of the shortcomings of a segmentation approach, areas such as the thorax
and abdomen are more error prone because of the great degree of variability between
patient morphologies. Using an atlas approach requires the assumption that certain sets
of attenuation coefficients will be sufficient in representing all patients in a given
population, and this can lead to significant errors particularly in lung and bone [12].
Also, the presence of tumors and metallic implants in the patient impacts the quantitative
accuracy of the atlases [2]. Small structures can be affected by misregistrations of
boundaries as well as warped non-rigid registered tissue atlases which are smoothed and
thus lose spatial resolution [12].
In a patient population where differences in anatomy, disease and pathology can
be significant, it is unlikely that a single atlas will provide an adequate match for all
individuals [16, 17]. Further, given the heterogeneity of body sizes and shapes even in a
normal healthy population, specialized atlases could provide more accurate
representations.
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Given such a diverse group, we hypothesized that atlas-based attenuation
correction could benefit from the use of atlases specialized to the population’s subgroups. Our preliminary study demonstrated that a µ-map from a gender-matched
individual with the closest body volume as a fraction of the Field of View (FoV) arguably
outperformed other µ-maps obtained through a segmentation or mapping approach [14].
The purpose of this experiment was to determine the extent of which body mass index
(BMI) and gender impact the quantitative accuracy of an atlas-based approach to
attenuation correction in PET. Here we expand upon these findings by comparing the
performance of several atlas approaches with standard CT corrected PET reconstructions.
In particular, we compare three different approaches to atlas map design, where
we consider the importance of Body Mass Index (BMI) and gender in generating an
acceptable match for attenuation correction of PET.

One approach incorporated

individuals from three BMI categories (Normal, Overweight, and Obese) and both
genders.

We called this atlas our fully amalgamated atlas.

Our second approach

incorporated individuals belonging to the same BMI categories. This resulted in three
atlases; normal; overweight; and obese. All three of these atlases included both genders
in equal numbers. Our third approach resulted in two atlases, which included only
members of the same gender in each. Both of these atlases incorporated individuals from
our three considered BMI categories.

2.2 Methods
Seventeen patients (11 males, 6 females; mean age = 58.1 ± 9.1 years), from a general
oncology population who had referrals for FDG-PET/CT scans were scanned in a
Discovery VCT PET/CT (General Electric Medical Systems, Waukesha, Wisconsin,
USA) and then subsequently scanned in a 3 Tesla Verio MRI (Siemens Medical,
Erlangen, Germany). Eligible patients included those with solitary pulmonary nodule
(SPN), non-small cell lung cancer, clinical stage III non-small cell lung cancer, limited
disease small cell lung cancer, thyroid cancer, germ cell tumors, colorectal cancer,
lymphoma and esophageal cancer. This group consisted of men and women, both with
normal, overweight, and obese BMI scores. This study was approved by our institute’s
Health Sciences Research Ethics Board.
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Patients were administered 5 MBq/Kg of FDG (to a maximum of 555 MBq) one
hour prior to the PET/CT, after fasting overnight. The PET acquisition was 3D with 210
seconds per table stop, free breathing and ungated.

Ordered-Subsets Expectation

Maximization (OSEM)–based reconstructions were done with 2 iterations, 28 subsets.
The PET images were composed of 128 x 128 matrices with pixel size of 5.47 mm × 5.47
mm and slice thickness of 3.27 mm.
The CT scans were acquired during free but shallow breathing, with 140 kVp, and
110 mAs. Reconstructions were performed with filtered back projection with a matrix
size of 512 × 512 and pixel size of 1.37 mm × 1.37 mm, , and slice thickness of 3.27 mm.
CTs were converted into µ-maps using the manufacturer’s algorithm on the PET/CT
console by down sampling through voxel averaging, resulting in a 128 × 128 matrix,
smoothed with a Gaussian filter (full-width half-maximum = 10 mm). Voxel values were
then replaced by applying a lookup table.
The MR images were acquired during breath holds at end of passive expiration
(functional residual capacity) with a 2D Turbo-FLASH sequence (TR = 786 ms, TE =
1.32 ms, 1 signal average, flip angle = 10˚, and pixel bandwidth of 630 Hz/pixel).
Images were composed of 256 x 256 matrices with pixel size of 1.95 mm × 1.95 mm, and
axial slice thickness of 5 mm without gaps, and an anterior/posterior phase encode
direction. Five table positions, each lasting 15 seconds for 36 slices, were acquired to
form whole-body images.
Radiofrequency (RF) transmission was done through the body coil and received
through elements of the spine array, large flex RF coils adjacent to the field of view
(FOV), and the body matrix. RF shading was reduced with prescan normalization prior to
each acquisition.
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2.2.1

Data Preparation and Preprocessing

Images from both MRI and PET/CT, including CT-based µ-maps, for the same patient
were co-registered using 3DSlicer’s Fast Nonrigid B-spline registration module [18] to
register the MRI dataset to the CT. This allowed us to simulate simultaneous PET/MRI
data sets.

2.2.2

Atlas Construction

The converted CT-based µ-maps and the resulting MRI/CT-based µ-map data pairs were
used to construct 6 atlases: averaged male atlas; an averaged female atlas; three averaged
BMI-specific atlases (obese >30, overweight 25-29.9, Normal 18.5-24.9) [21]; and a
single atlas, nonspecific to gender or BMI, which we refer to as a fully amalgamated
atlas.
Gender specific atlases were created by arbitrarily selecting a patient from each
gender. Three male patients, one from each of the BMI categories being considered,
were then registered to the arbitrarily selected male in the previous step. Registrations
were done first between CT scans and the resulting transformations were then applied to
the corresponding MR images from the same patients. Co-registered images from the
same modalities were averaged together, creating an MRI & CT µ-map male genderspecific atlas pair. The same steps were applied to three additional female patient scans
to construct a female gender-specific atlas pair.
BMI specific atlases were created by arbitrarily selecting a patient from each of
the three BMI categories; normal; overweight; and obese. Three additional patients with
normal BMIs, one from the same gender and two from the opposite gender of the
arbitrarily selected patient with a normal BMI in the previous step were registered to the
initially chosen normal-BMI patient. Registrations were done between CT scans first and
the resulting transformations were then applied to the corresponding MR images from the
same patients. Co-registered images from the same modalities were averaged together,
creating an MRI & CT µ-map normal-BMI atlas pair. The same steps were repeated for
the overweight and obese categories to construct the remaining two BMI atlas pairs.
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The fully amalgamated atlas included six patients, three from each gender and
two from each of the three BMI categories used. As with the previously described
approaches, one patient was arbitrarily chosen and the remaining five patients were
registered to them. Again, starting with the registration between CT scans and then
applying the same transformations to the corresponding patient MR images.

Once

registered, images from the same modalities were averaged together into an amalgamated
MRI & CT µ-map atlas pair.
All registrations were done with 3D Slicer’s Fast Non-rigid B-spline registration
module. Registrations of MRI to CT images of the same patient were done with 20
iterations, 5 grid points on the interior of the fixed image, 100 histogram bins and 50,000
spatial samples were used for Mattes Mutual Information [19] while all other parameters
were set to default values.

These parameters were selected by visually assessing

registrations of preliminary data with various combinations of parameters, and selecting
settings that consistently yielded satisfactorily aligned images.

Inter-patient CT

registrations during atlas construction were done with 60 iterations, a grid size of 10, 100
histogram bins, and 250,000 spatial samples.

Transformations from inter-patient

registrations were then applied to the corresponding MR images with the Resample
Image (BRAINS) module in 3D Slicer [20]. Averaging of same-modality images was
done with software developed in house with Matlab 2010b, to create MRI and CT-based
µ-map atlas pairs.

2.2.3

Correcting for Attenuation in Patient Data with Atlases

Attenuation in each PET image was corrected using the BMI-specific and gender-specific
atlases, which corresponded to the patient’s BMI and gender, the fully amalgamated atlas
and the corresponding CT-based µ-map in separate reconstructions (See Figure 2-1). All
four PET reconstructions were performed on scans for patients not included in the
construction of the atlases. This was done by registering the MRI components of each
atlas pair to the patient’s MRI. This registration was performed with the same method
used in the inter-patient registrations during the construction of the atlas.

The

transformations required to align these volumes were saved in a separate file and applied
to the corresponding CT µ-map components of each atlas, again using the Resample
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Image (BRAINS) module in 3D Slicer [20]. The newly registered atlas CT µ-maps were
then loaded, along with the original PET emission data, onto the GE Discovery VCT
PET/CT console where reconstructions were performed in the same fashion as the
originally corrected PET, only now with the registered atlas µ-maps. This was performed
using ordered subset expectation maximization (OSEM) with three iterations and eight
groups. Comparisons between PET reconstructions were preformed across all voxels and
tissue-specific regions (soft-tissue, bone, and lung).

Figure 2-1: Atlas-based Reconstruction Comparison: A) A standard PET reconstruction for comparison. The
CT image is converted into a mapping of attenuation values. This is then used to correct for the attenuation in
the PET image. B) In our Atlas-based approach, the MRI component of the atlas is registered to the patient’s
MRI. The transformations used to register these MR images are then applied to the CTAC component of the
Atlas. This registered CTAC is then used to correct for attenuation in the patient PET. C) We then compare
the Atlas-based Corrected PETs to the standard CT corrected PET.
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2.2.4

Data Analysis

Data analysis was performed in Matlab v7.11 (The MathWorks, MA, USA), and
methodology was adapted from Marshall et al, 2011. Differences between the line
integrals through PET images reconstructed with Atlas-based µ-maps and CT-based µmaps were calculated. Least-squares regression lines of best fit (LOBFs) were calculated
for scatter plots of Atlas and CT based µ-map line integrals. Measurements included
LOBFs mean slope, y-intercept, correlation coefficient (R2), and relative error.

In

addition to this global analysis, ten volumes of interest (VOIs) were selected to include a
variety of tissues. These VOIs consisted of 3x3x3 voxels and included the caudate
nucleus, cerebellum, right upper lung, aortic arch, cardiac septum, vertebral body of T8,
liver, spinous process of L2, sigmoid colon, iliacus. The mean relative percent error
calculated by,

and standard deviation for each VOI were calculated, where CT was the sum of voxel
values in the VOI from the CT corrected PET image, AT was the sum of voxel values in
the same VOI in the atlas corrected PET image, and n was the number of VOI being
averaged together. This was calculated for all VOIs within each atlas, as well as within
each atlas design approach.

2.3 Results
Examples of the two gender-based, three BMI-based, and a fully amalgamated atlas µmap are shown in Figure 2-2. A summary of values from the global analysis through
scatter plots are shown in Table 2-1, and the results from our local analysis of VOIs are
shown in Figure 2-3. A detailed breakdown of each VOI for each atlas used is presented
in Table 2-2.

Figure 2-2: Coronal µ-map images. A) A single CTAC. B) An averaged Normal BMI atlas. C) An averaged overweight
BMI atlas. D) An averaged obese BMI atlas. E) An averaged male atlas. F) An averaged female atlas. G) An averaged
fully amalgamated atlas
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Figure 2-3: Mean relative percent error for VOIs from PET images corrected with each
approach. Error bars indicating standard deviations for each category.

The results of the global analysis showed that the fully amalgamated approach to
atlas design did not perform as well as the gender-based and the BMI-based approaches.
The LOBFs for scatter plots comparing gender-based atlas corrected PETs with standard
CT corrected PETs yielded a mean slope = 0.9190, a mean y-intercept = 0.0003, and a
mean R2 = 0.9097. The BMI-based atlas reconstructed PETs plotted against the standard
CT corrected PETs resulted in similar results with a mean slope = 0.9133, mean yintercept = 0.0019, and mean R2 = 0.9082. The fully amalgamated atlas corrected PETs
versus the standard CT corrected PETs scatter plots produced LOBFs with a mean slope
= 0.8606, a mean y-intercept = 0.0178, and a mean R2 = 0.8465.
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Figure 2-4 shows an example of a scatter plot between an atlas corrected PET
reconstruction and the corresponding CT corrected PET reconstruction. Looking towards
the point of origin, we can see data points flaring out from the LOBF. These are
consistent with all reconstructions, and are the result of mismatches in the lung region
and related tissue boundaries. A large source of error originates from misregistration in
lung tissue boundaries, particularly between the lower right lung and the liver as well as
the around the mediastinum.

Figure 2-4: Scatter plot of Overweight BMI-based atlas corrected PET versus CTAC
reconstructed PET (Patient 12)
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The local analysis of 10 VOIs over the three different types of BMI-based atlas
corrected PETs, two gender-based atlas corrected PETs, and the fully amalgamated atlas
corrected PETs showed that the performance rankings of these methods were similar to
those found in the global analysis, in that a gender-based approach consistently
outperformed the other two approaches. A comparison of relative percent errors showed
the gender-based corrections had a mean value = 9.786 with a standard deviation (S.D.) =
7.239, the fully amalgamated approach had a mean value = 11.093 with a S.D. = 6.636,
and the BMI-based corrections mean value = 12.306 and S.D. = 6.900. A further breakdown of the atlas design approach groups into the individual atlases used, showed little
difference between the BMI categories. The relative percent errors for the normal BMI
category corrections had a mean value = 11.375 and S.D. = 5.673, the overweight BMI
mean value = 12.761 and S.D. = 5.316, and the obese BMI mean value = 12.026 and S.D.
= 5.119. However, when comparing individual gender atlases, we see that the female
atlas had a noticeably lower mean relative percent error. The male atlas corrections
yielded a mean relative percent error = 12.112 and S.D. = 7.725, but the female atlas
corrections had a mean value = 7.702 with S.D. = 5.806. The smaller sample size in the
female reconstructions may have contributed to this difference between genders.
Generally, VOIs occurring on or close to boundaries between tissues with
significantly different attenuation values showed a greater relative error between atlas
and original CTAC reconstructions. VOIs central to a particular tissue type showed
much smaller errors. Differences between mean values for any VOIs were often as great
as the differences between the design approaches themselves. The VOIs placed within
soft tissues performed much better than those placed within lung or bony tissues. Two
VOIs with consistently lower errors were the Caudate Nucleus and the Cerebellum. The
largest errors were found in bony tissues, specifically the iliacus and the spinous process
of L2. The remaining VOIs had intermediate mean error and S.D. values and were all
found in soft tissues of the torso.
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2.4 Registration
Accurate alignment of image data from multiple modalities is important in research,
diagnosis and treatment. This process of image alignment or registration uses intensity
values in the image voxels to optimize the transformations, which align the images in a
three dimensional volume. Depending on the types of images being registered and the
computing resources available, there are a variety of different methods and parameter
settings that can be used but all are composed of a method to perform geometrical
transformations to an image, a similarity metric, and an optimizer to find the best
solution.
All transformations can be divided into two main categories, rigid and non-rigid.
Rigid transformations maintain all relative distances between points within the same
image, thus limiting all rigid transformations to rotations and translations making for 6
degrees of freedom.

Non-rigid transformations include affine and b-spline

transformations. Affine transformations allow for scaling and shearing in addition to
rotations and translations. This gives us an additional 6 degrees of freedom, making for a
total of 12 that can be used to register the images. Bspline transformations are performed
by fitting complex curves through sets of control points in an image and then allowing
each control point 6 degrees of freedom by translation. These complex curves are
composed of polynomial curve segments. Although this method is not flexible enough
for large rotations it does allow for warping, which is very useful when matching
interpatient scans. In this scenario patients are always scanned in the same position,
hence rotations will not be needed but variations between corresponding anatomies will
require local warping.
Once a set of transformations have been applied to an image, we need a way to
determine whether the transformed image is more or less similar to the target image. We
perform this evaluation with a similarity metric, such as mean squared difference,
normalized cross correlation, or Mattes mutual information. A mean squared difference
is the sum of the squared differences between corresponding pixel values of two images
divided by the product of the image dimensions. For example, we would find the mean
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squared difference (MSD) of image A and image B, each of which is i pixels in the x-axis
and j pixels in the y-axis by the following equation:

However, in addition to being potentially time consuming this method is not
useful for registering different modalities. Normalized cross correlation (NCC) estimates
the degree of correlation between two images, where a value of 1 is a perfect correlation
and a value of 0 means no correlation. This measure works particularly well for images
of the same modality and is found with the following equation:

The third example of a similarity metric and the one we chose to apply to our
registrations is Mattes mutual information.

This metric calculates the amount of

statistical dependence between two images, where the mutual information between them
is maximized when the images are aligned.

This metric is effective in measuring

similarity between images of different modalities as well as similar modalities and can be
found with the following equation:

where H is the Shannon entropy of an image. The entropy of an image can be found by
using the following equation:
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where pA(a) is the probability of a particular intensity value of a location within the
image.
Finally, an optimizer is an algorithm used to find a global solution to our registration
problem. It modifies transformation parameters and similarity metrics in order to find an
optimal solution. The software package used in our study, 3D Slicer, mainly uses oneplus-one optimization and gradient-linesearch to find a best solution.

2.5 Discussion
The goal of this work was to explore the importance of gender and BMI in the
quantitative accuracy of attenuation correction performed with an atlas-based µ-map in
PET/MRI. We evaluated the performance of these approaches both globally and locally
to identify their strengths and weaknesses. We will discuss some of the challenges faced
with all of our approaches which include error-prone tissue boundaries, variable densities
found in lung volumes, and similarly in bones. We will also propose some strategies to
address these challenges with the current approaches.
One of the largest sources of error is related to registration rather than to the
approach to atlas design. As mentioned previously, VOIs on or close to tissue boundaries
were error prone and this was present amongst all of our approaches. An example of this
can be seen in a plot of voxel intensity profiles in Figure 2-5a, which have been taken
from the same transaxial slice through the chest of a patient’s PET images reconstructed
with standard CTAC in Figure 2-5b and the gender-based atlas shown in Figure 2-5c.
Here we can see the profiles differing most at the boundary between the lung and liver, as
well as the boundary around the mediastinum. This may in part be due to all tissues
being subject to the same deformation parameters during registration. More sophisticated
registration strategies that include warping penalties for more rigid structures like bone
may help improve the alignment of these structures. In particular, the boundary between
the lower right lung and the liver were often misaligned. This may have also been
improved with a more thorough search for optimized registration parameters and
similarity metrics. Thus, more work needs to be done to optimize the parameters related
to registration of the atlas to patient scan.
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The magnitude of the errors found within lung and bony tissues may be largely
due to the variation that can be found within a population with a mean age of 60 years, as
was the case with our participants. Size and density of lungs can vary considerably
between patients and even among different areas within the same patient. As such, this
represents an important challenge for all MRI-based approaches to attenuation correction.
The variations in linear attenuation values within lung tissue are often indicative of the
health or pathology present. Whether one chooses a segmentation or an atlas-based
approach, the value being assigned will inevitably be a theoretical one and not necessarily
reflective of the true values present within the patient. This can lead to under-correction
within active lung tumors, resulting in an apparent reduction in uptake values, which may
impact decisions regarding treatment.
Recently, there has been work done using lung signal obtained from short echo
time MRI sequences to produce a mapping of MRI voxel intensity values to linear
attenuation coefficients (96).

This has the potential to provide more accurate and

personalized mapping of values within the lungs of an individual patient. Incorporating
this mapping technique strictly to the lung volumes within atlases could remove the
majority of error and variability that occurs by providing a personalized continuous
distribution of µ values, rather than the averaged distribution of µ values from a
population in an atlas, or a single theoretical µ value from segmentation.
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Figure 2-5a: Intensity profiles through a CTAC reconstructed PET (orange) and a Male
Gender-based atlas reconstructed PET (blue) for Patient 12.

Figure 2-5b: CTAC reconstructed PET Figure 2-5c:
Gender-based atlas
with line indicating profile plotted in reconstructed PET with line indicating
Figure 4a.
profile plotted in Figure 4a.
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Similar to the variations in density found in lung tissue, bone densities can vary
greatly from patient to patient. In addition to inter-patient variations in density, bones
also display a heterogeneous distribution of attenuation coefficients within the same
patient. Our heterogeneous distribution of attenuation values within bones are still only
representative of average bone attenuation coefficients. Our results suggest that these
values cannot account for anomalies or individual differences caused by conditions, such
as osteoporosis or bones lesions.
As with the short echo time sequences developed to obtain signal from
lung, UTE sequence development has given rise to techniques that can obtain signal from
cortical bone. Including a protocol such as this at the time of the patient scan could
provide additional information for mapping underlying bone structures. Having a patient
specific mapping instead of relying on an averaged representation would help improve
quantitative accuracy and assessment of bone pathologies.

2.6

Conclusion

All three approaches to atlas design displayed similar error prone areas that could be
improved by incorporating specialized tissue-specific MRI sequences and related
mapping algorithms for lung and bone. Ultimately, it was the gender-based approach to
atlas design that provided the best quantitative accuracy, both in global and local
analysis.
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Chapter 3
3.1

Summary

Correcting for attenuation in Positron Emission Tomography/Magnetic Resonance
Imaging (PET/MRI) is difficult because there is no known relationship between MR
signal and attenuation coefficients (µ) for 511 keV photons. Approaches to MRI-based
attenuation correction can be divided into 3 categories; segmentation, atlas-based, and
mapping.
Segmentation approaches divide an MR image into different tissue classes based
on voxel intensity and location, and assign theoretical attenuation coefficients to each
class, based on a look-up table.

Although this approach gives us patient specific

attenuation maps and can work well with tissues or mediums with consistent attenuation
coefficients, this approach does have difficulty in accounting for bone and lungs (due to
the lack of signal obtained from these in MRI). It also has difficulty accounting for
image truncation, which can occur if part of the patient is too far from the isocenter of the
main field.

Also, signal noise can often cause some misclassification or incorrect

segmentation.
An atlas-based approach infers a distribution of electron densities from an MRI
scan using the atlas map registration approach. This relies upon spatially aligning a 3D
anatomical atlas of attenuation coefficients to an MRI scan, and then using that atlas as
the basis for attenuation correction of the PET scan.

Unlike current segmentation

approaches, a properly aligned atlas will contain a heterogeneous mapping of both lungs
and bones, which may be representative of a particular population, but they may not be a
precise representation of the individual. Along a similar theme, individual morphology
or deviations from the population norm represented in the atlas cannot be accounted for
with the current atlas methods. This being said, current atlas-based methods can provide
corrections within clinically acceptable margins of error without lengthy specific MRI
sequences.
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Mapping involves creating a function that will convert MRI voxels to linear
attenuation coefficients. Although, fundamentally, the physics behind how we achieve
contrast in each modality are very different and there is no known relationship between
them that could be applied across all tissues, this approach has great potential to address
some of the shortcomings that are found in the other two approaches, such as making
assumptions about linear attenuation coefficients and assigning uniform values to areas of
inhomogeneity, or making assumptions about anatomy.
In our study, atlas corrected PET images were compared to CT corrected PET
reconstructions across all voxels and tissue-specific regions. The majority of errors were
more related to registration than to atlas design approach. In particular, most errors were
observed in the chest area, focused around the boundary between the right lung and liver,
and boundaries around the mediastinum. Further work towards optimizing registration
parameters for atlas-to-patient matching is required. Ultimately, we successfully created
atlas µ-maps based on matching BMI, matching gender, and a non-specific BMI or
gender. All three approaches to atlas design show promise as a way to correct for
attenuation in PET/MRI, based on the observed accuracy, speed, and potential
applications.

3.2 Future Directions and Limitations
The current method of attenuation correction being used by Siemens in their first clinical
PET/MRI uses a 2-point Dixon MRI sequence which, when segmented yield a 4compartment (Air, Lung, Fat, Soft tissue) map [1]. This method has been evaluated in a
35 patient study and found to produce no statistically significant difference concerning
anatomical localization of PET positive lesions when compared to a low-dose CT [2].
Other similar approaches have been proposed, which provide more tissue classes, such as
with Hoffman et al. [3], where they use an 18 second per bed position dual-echo
sequence and a 2-point Dixon method to generate fat- and water-only images and then
segment into five classes; air, lungs, fat tissue, a fat-non-fat tissue mixture, and non-fat
tissue. Hofmann’s study showed a relative error between PET images reconstructed with
CTAC and segmented MRI, for VOIs in regions of normal physiologic uptake were
14.1% ± 10.2%. This was greater than their atlas and pattern recognition approach at
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7.5% ± 7.9%, in part because the segmented approach did not include bone. When
comparing the segmented MRI with the segmented CT without bone, 14.1% ± 10.2% and
7.6% ± 8.2% respectively, they differed by only 6.5%. A large portion of this error might
be explained by the substantial increase incurred when going from the non-segmented
CTAC excluding bone to the segmented CTAC excluding bone, 1.0% ± 0.8% to 10.2% ±
7.5% respectively. Segmentation could be increasing the amount of error by neglecting
to represent the heterogeneities naturally present in patient tissues.
Although segmentation approaches perform reasonably well and will improve,
they still have the shortcoming of always assigning the same theoretical value to a
classified tissue type.

This seems to work well with soft tissues and fat, which

themselves maintain close agreement with these values, regardless of patient health. But
bone and lungs do not follow the same trends. The density of lung tissue in a patient is
often reflective of their lung health and there are a variety of different approaches to
capturing this with MRI [4-7].
Strict approaches to MR-based attenuation correction have inherent limitations,
and to date many approaches have not attempted to combine methodologies to capitalize
on the strengths of one that overlap the weakness of the other. For example, perhaps
better accuracy could be obtained in the thorax if the lung compartment of a segmentation
approach was replaced with a mapping method capable of estimating lung density. Our
group found a relationship between MRI and CT values in lung tissue was established
with a 750µs echo-time cardiac-gated 2-dimensional turbo fast low-angle shot sequence.
This demonstrated that µ-coefficients can be inferred in lung with MRI to correct for
attenuation in PET, improving quantification [8].
It has been shown that for a CT energy of ~80keV the linear attenuation
coefficient for water = 0.184 cm-1 and for bone = 0.428 cm-1. At the 511keV energies of
PET imaging, these values are 0.096 cm-1 for water and 0.172 cm-1 for bone. We can see
that at both energies, current approaches that classify bone as soft tissue will cause
quantitative errors. Recently, work has been done to image cortical bone with MRI [911]. These methods do not make assumptions about patient anatomy, which make them
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ideal for studies involving patient abnormalities. Whole body PET/MR images would
stand to benefit from the incorporation of techniques like these, allowing for the
replacement of what currently gets evaluated as soft tissue [1].
Promising results have also been shown with MRI measurements of trabecular
bone with respect to osteoporosis and osteoarthritis [12, 13] and are able to improve
fracture risk prediction and monitoring of osteoporosis treatment [14-17]. Incorporating
these images into an MR-based attenuation map may provide us with the much needed
values to correct for the most attenuating tissue in the human body, bringing us that much
closer to quantitative accuracy that can contend with some of PET/MRI’s predecessors.
However, acquisition times for these types of images can be long and it may not be
feasible to use them in most clinical scans. For example, Keereman et al’s UTE approach
to imaging cortical bone required a 6 minute acquisition time and Baum et al’s approach
to imaging cortical bone required a ~7 minute scan. This doesn’t take into account any of
the post processing of data that would occur to obtain the necessary information to
generate attenuation values.
The atlas-based approaches we have designed for these experiments demonstrate
that, within the constraints of the population they were designed for, they show promise.
However, in Ontario, there are nine oncological indications (diagnostic situations or
conditions) that are eligible for PET/CT, when there is sufficient evidence both that the
PET scan will benefit the patient and has advantages over other testing tools
(www.petscansontario.ca).

These indications often show a great deal of variation

between patients, with regard to location and size, among other characteristics. In a
similar fashion, lung and osseous tissues can have considerable variation between
patients, independent of gender and BMI. In fact, variation can also be found across
similar tissues within the same patient. Again, this discrepancy between patients and
heterogeneity within patients present an important challenge to any MRI-based PET
attenuation correction strategy.
In developing our atlas-maps, we also considered a database approach where we
registered each MRI from a collection of patient MRI/CTAC data pairs to a patient
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specific MRI.

The transformations from the registration with the optimal mutual

information score would be used on the matching CTAC from the collection. This
registered CTAC would then be used to correct for attenuation in the patient scan in the
same fashion as the atlases. Again, all registrations were performed with a fast non-rigid
B-spline registration with mutual information metric.
In a global analysis by linear regression of scatter plots between the database
approach and standard CTAC corrected PET images, we still found the characteristic
flare out of data points from the line of best fit, similar to the atlas corrected PET images.
However, the database approach performed poorly overall, with the LOBFs mean slope =
0.8342, mean y-intercept = 0.00072, and R2 = 0.803. This was consistent with the local
analysis, where the mean relative error over the same 10 VOIs was 20.311% ± 14.962,
and also showing problems with tissue boundaries.
The size of the database (17 patients) appeared to be the largest contributing
factor to its poor performance. Although the weighting of errors between tissue types
seemed to be similar for all methods, the atlases could mitigate this through the washing
out of discrepancies through the averaging that took place during atlas construction.
Given a larger database with more options to find patients with more closely matched
compositions, it would likely improve the performance of this method. Neither of these
approaches were capable of accounting for individual variance between patients alone
and ultimately will only be able to provide a closest match based on relative comparisons,
instead of an absolute measure.

However, with improved registration this may be

sufficient for specific clinical applications.
As mentioned previously, we used Mattes mutual information as the metric for
our registration of images [18]. Perhaps this final similarity score, obtained during a
registration, could be used to determine whether the final atlas is suitable for attenuation
correction of the patient’s PET. Further work would be needed to determine a similarity
threshold value for an atlas’ viability, or explore other methods to measure when an atlas
may not be appropriate to use. In circumstances where this threshold has been passed,
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this may be an opportunity to incorporate some of the above mentioned techniques to
help identify unique morphologies or signal the need for operator input.

3.3 Conclusion
This thesis has demonstrated three design approaches to atlas-based µ-maps for use in
PET/MRI: averaged gender specific, averaged BMI category specific, and a fully
amalgamated atlas.

All three approaches showed promise as ways to correct for

attenuation. The gender specific approach performed best for local and global analysis,
while BMI specific atlases outperformed the amalgamated approach in global, but not
local analysis. All approaches had similar error prone areas, which may indicate a
limitation of the general approach and not a limitation of the design methods. Although
further work to optimize registration could improve the overall performance, anatomy
where inter-patient variability of attenuation coefficients play a greater role than
morphology, would perhaps perform better by implementing a mapping strategy to
determine patient specific densities.
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